New drug targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This study is testing a new experimental drug called ETX-19477 in people with advanced solid tumors, including breast, ovarian, prostate, and other cancers that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink…
Phase: PHASE1, PHASE2 • Sponsor: 858 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC